1. Home
  2. KALA vs NAII Comparison

KALA vs NAII Comparison

Compare KALA & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALA
  • NAII
  • Stock Information
  • Founded
  • KALA 2009
  • NAII 1980
  • Country
  • KALA United States
  • NAII United States
  • Employees
  • KALA 43
  • NAII N/A
  • Industry
  • KALA Biotechnology: Pharmaceutical Preparations
  • NAII Medicinal Chemicals and Botanical Products
  • Sector
  • KALA Health Care
  • NAII Health Care
  • Exchange
  • KALA Nasdaq
  • NAII Nasdaq
  • Market Cap
  • KALA 27.3M
  • NAII 28.0M
  • IPO Year
  • KALA 2017
  • NAII 1987
  • Fundamental
  • Price
  • KALA $5.92
  • NAII $4.24
  • Analyst Decision
  • KALA Strong Buy
  • NAII
  • Analyst Count
  • KALA 2
  • NAII 0
  • Target Price
  • KALA $15.00
  • NAII N/A
  • AVG Volume (30 Days)
  • KALA 31.3K
  • NAII 9.8K
  • Earning Date
  • KALA 11-12-2024
  • NAII 02-11-2025
  • Dividend Yield
  • KALA N/A
  • NAII N/A
  • EPS Growth
  • KALA N/A
  • NAII N/A
  • EPS
  • KALA N/A
  • NAII N/A
  • Revenue
  • KALA N/A
  • NAII $112,977,000.00
  • Revenue This Year
  • KALA N/A
  • NAII N/A
  • Revenue Next Year
  • KALA N/A
  • NAII N/A
  • P/E Ratio
  • KALA N/A
  • NAII N/A
  • Revenue Growth
  • KALA N/A
  • NAII N/A
  • 52 Week Low
  • KALA $4.21
  • NAII $4.02
  • 52 Week High
  • KALA $9.25
  • NAII $7.26
  • Technical
  • Relative Strength Index (RSI)
  • KALA 41.69
  • NAII 44.45
  • Support Level
  • KALA $5.67
  • NAII $4.02
  • Resistance Level
  • KALA $6.23
  • NAII $4.33
  • Average True Range (ATR)
  • KALA 0.31
  • NAII 0.15
  • MACD
  • KALA -0.07
  • NAII -0.01
  • Stochastic Oscillator
  • KALA 21.55
  • NAII 34.37

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About NAII Natural Alternatives International Inc.

Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segment. The company derives the majority of revenue from Private-Label Contract Manufacturing which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.

Share on Social Networks: